Bruck Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bruck Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $73.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bruck Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $73.5K Trade | TransData Nexus

Bruck Pharma Private Limited

Indian Pharmaceutical Exporter · Immunosuppressants Specialist · $73.5K Total Trade · DGFT Verified

Bruck Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $73.5K across 5 products in 3 therapeutic categories. Based on 28 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Everolimus ($33.7K), Busulfan ($19.1K), Vinblastine ($13.0K).

Bruck Pharma Private Limited — Export Portfolio & Destination Treemap

Bruck Pharma Private Limited pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bruck Pharma Private Limited? — Company Overview & Market Position

Bruck Pharma Private Limited, established on August 23, 1984, is a privately held pharmaceutical company headquartered in Goregaon East, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24239MH1984PTC416799. As of the latest available data, Bruck Pharma has an authorized capital of ₹5.00 crore and a paid-up capital of ₹2.68 crore.

The company specializes in the manufacturing and marketing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Bruck Pharma focuses on providing high-quality medicines across various therapeutic segments, with a particular emphasis on oncology and immunosuppressants. Their product portfolio is designed to meet the needs of specialist physicians and patients globally.

What Does Bruck Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Everolimus$33.7K 2Busulfan

Product Portfolio — Top 5 by Export Value

Bruck Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Everolimus	Immunosuppressants	$33.7K	3	0.1%	10
2	Busulfan	Advanced Oncology	$19.1K	3	0.4%	7
3	Vinblastine	Oncology	$13.0K	13	1.7%	14
4	Chlorambucil	Advanced Oncology	$4.8K	6	1.4%	6
5	Lomustine	Advanced Oncology	$2.8K	3	2.7%	10

Bruck Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $73.5K. The top category is Immunosuppressants (45.9% of portfolio), followed by Advanced Oncology (36.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Bruck Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Bruck Pharma operates a manufacturing facility located in Daman, India. The plant specializes in the production of cytotoxic products, including liquid injections, lyophilized injections, tablets, and capsules. The facility is equipped with state-of-the-art manufacturing and packaging technologies to ensure the production of high-quality pharmaceutical products. Additionally, the company has significant expansion in research and development (R&D), with over three decades of experience in various sectors of the healthcare industry.

3Key Leadership

Bruck Pharma is led by a team of experienced professionals committed to the company's mission of delivering quality medicines. The key executives include:

Shirish Devendra Kejriwal – Director
Anshu Devendra Kejriwal – Director

Both directors have been instrumental in steering the company's strategic direction and growth. Their leadership has been pivotal in expanding Bruck Pharma's product portfolio and enhancing its manufacturing capabilities.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bruck Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Bruck Pharma's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, indicate a total export value of $73,000 USD across 28 shipments. The company exports five products across three therapeutic categories, with the top five products being Everolimus, Busulfan, Vinblastine, Chlorambucil, and Lomustine. These products are primarily targeted at markets in the United States, European Union, United Kingdom, Australia, and Japan. The company's focus on oncology and immunosuppressant drugs aligns with the therapeutic needs of these regions. However, specific regulatory filings, approvals, and market access statuses in these countries are not detailed in the available data.

2Emerging Markets

Bruck Pharma's export data suggests a presence in emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's focus on oncology and immunosuppressant drugs positions it to meet the therapeutic needs of these regions. While the data does not specify WHO prequalification status, the company's adherence to WHO cGMP standards indicates a commitment to quality that is essential for accessing these markets.

3Geographic Strategy

Bruck Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Bruck Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided data. The company's adherence to WHO cGMP standards suggests a commitment to quality, which is essential for FDA approvals. However, without explicit information, a comprehensive assessment of the company's FDA status cannot be made.

2WHO & EU GMP

Bruck Pharma's manufacturing facility is accredited with WHO cGMP and ISO 9001:2015 certifications. These accreditations indicate compliance with international quality standards, which are crucial for accessing global markets, including the European Union. However, specific details regarding EU GMP certificates and EDQM status are not available in the provided data.

3CDSCO & Indian Regulatory

Bruck Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, as indicated by its compliance with WHO cGMP standards. The company's export activities, as per TransData Nexus proprietary trade data from 2022 to 2026, suggest that it has obtained necessary export No Objection Certificates (NOCs) for its products. However, specific details regarding CDSCO approvals and state drug controller approvals are not detailed in the available data.

Bruck Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Bruck Pharma operates in the oncology and immunosuppressant drug segments, which are competitive fields with several established players. While specific market share comparisons and head-to-head analyses are not available in the provided data, the company's focus on high-quality, affordable medicines positions it to compete effectively in these therapeutic areas. The company's adherence to international quality standards, such as WHO cGMP and ISO 9001:2015, enhances its competitiveness in the global market.

2Key Differentiators

Bruck Pharma's key differentiators include its focus on specialty biopharmaceuticals, particularly in the oncology and immunosuppressant segments, and its commitment to quality, as evidenced by its WHO cGMP and ISO 9001:2015 certifications. The company's significant expansion in R&D and manufacturing capabilities, along with its experienced leadership team, further distinguish it in the pharmaceutical industry.

3Strategic Position

Bruck Pharma's current strategic direction focuses on the manufacturing and marketing of specialty pharmaceutical formulations, with a particular emphasis on oncology and immunosuppressant drugs. The company's expansion in R&D and manufacturing capabilities indicates a commitment to growth and innovation. Future outlooks suggest a continued focus on quality and affordability, aiming to meet the evolving needs of global markets.

Buyer Due Diligence Brief — Evaluating Bruck Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Bruck Pharma's export data indicates a total export value of $73,000 USD across 28 shipments from 2022 to 2026, suggesting a consistent export volume. The company's adherence to WHO cGMP and ISO 9001:2015 standards, along with its significant expansion in R&D and manufacturing capabilities, indicate reliability and a commitment to quality. However, without specific data on order fulfillment rates, lead times, and customer feedback, a comprehensive assessment of the company's supplier performance cannot be made.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm through the FDA's official database or Bruck Pharma's official communications.
WHO-GMP: Verify via the World Health Organization's official website or Bruck Pharma's official communications.
EU GMP: Check the European Medicines Agency's official website or Bruck Pharma's official communications.

Frequently Asked Questions — Bruck Pharma Private Limited

How many pharmaceutical products does Bruck Pharma Private Limited export from India?

Bruck Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Everolimus ($33.7K), Busulfan ($19.1K), Vinblastine ($13.0K), Chlorambucil ($4.8K), Lomustine ($2.8K). Total export value is $73.5K.

What is Bruck Pharma Private Limited's total pharmaceutical export value?

Bruck Pharma Private Limited's total pharmaceutical export value is $73.5K, based on 28 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Bruck Pharma Private Limited cover?

Bruck Pharma Private Limited exports across 3 therapeutic categories. The largest are Immunosuppressants (45.9%, 1 products), Advanced Oncology (36.3%, 3 products), Oncology (17.7%, 1 products).

Get Full Bruck Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.